Survival analyses of patients with AML with or without IDH1 and IDH2 mutations. (A) Kaplan-Meier estimates of OS for all AML patients. (B) OS for AML patients with normal karyotypes. (C) OS for patients with intermediate-risk AML and FLT3^mutant and NPM1^mutant. (D) OS for patients with intermediate-risk AML and FLT3^wild-type and NPM1^mutant. (E) OS for patients with intermediate-risk AML and FLT3^wild-type and NPM1^wild-type. (F) EFS for patients with intermediate-risk AML and FLT3^wild-type and NPM1^wild-type. Survival curves in red represent cases with IDH1^mutant; those in green, IDH2^mutant; and those in black, cases with IDH1^wild-type and IDH2^wild-type, respectively. The log-rank P value is indicated per Kaplan-Meier analysis.